Synthetic Biology Firm Gen9 Raises $25M | GenomeWeb

NEW YORK (GenomeWeb) – Synthetic biology firm Gen9 has raised $25 million in a private financing round, its president and CEO confirmed to GenomeWeb Daily News.

The company disclosed the financing in a document filed with the US Securities and Exchange Commission last week. Gen9 President and CEO Kevin Munelly told GWDN in an email today that proceeds from the financing will be used to "expand our team and advance additional products and services that will further accelerate the design-build-test cycle for our customers."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.